May
25
 

Big business cashing in on reproductive services boom

The cliché “bundles of joy” has two meanings in the assisted reproduction industry: babies and cash. Keen businessmen are scrambling to take advantage of this burgeoning area of the health sector.

This was evident last week when reproductive services corporation Virtus Health conducted a hugely successful IPO. The market priced the shares of  Australia’s largest reproductive services provider, at A$5.68. The company is now valued at $449 million.

Virtus has become a behemoth. It owns almost 50 fertility clinics, day hospitals, and laboratories across Victoria, NSW and Queensland. It has also established a low-cost clinic in each state that targets ''a new segment of the market for whom fertility treatments were previously unaffordable''. The company employs over 80 fertility specialists, supported by 650 staff. It performed about one-third of all of Australia’s 39,000 fertility cycles last year. According to Virtus’s prospectus, IVF cycles and other assisted reproductive services generated revenue of more than $350 million.

Virtus has now set its eyes on expansion into Asia. CEO Sue Channon told the Australian Financial Review (AFR) that “The Asia-Pacific, China, India and Middle East markets are very immature and highly fragmented and we are looking for opportunities in these areas at the moment”.

AFR finance expert Michael Stutchbury said that “Virtus is in a bit of a sweet spot as it’s a unique offering, IVF is not listed anywhere else in the world [and] healthcare is a strong growth area”. Even the Wall Street Journal is following Virtus’s growth with keen interest. As The Australian punned, this is “a fertile ground” for investment. 



This article is published by Xavier Symons and BioEdge.org under a Creative Commons licence. You may republish it or translate it free of charge with attribution for non-commercial purposes following these guidelines. If you teach at a university we ask that your department make a donation. Commercial media must contact us for permission and fees. Some articles on this site are published under different terms.

comments powered by Disqus
 

 Search BioEdge

 Subscribe to BioEdge newsletter
rss Subscribe to BioEdge RSS feed


 Recent Posts
Australian Senate votes down euthanasia bill
18 Aug 2018
Direct-to-consumer genetic testing is booming, but ethical concerns remain
18 Aug 2018
Should doctors’ social media profiles be scrutinised?
18 Aug 2018
Introducing Snapchat Dysmorphia
17 Aug 2018
Is the BMA introducing ‘backdoor euthanasia’?
17 Aug 2018

Home | About Us | Contact Us | rss RSS | Archive | Bookmark and Share | michael@bioedge.org

BioEdge - New Media Foundation Ltd © 2004 - 2009 All rights reserved -- Powered by Encyclomedia